The eighth international childhood acute lymphoblastic leukemia workshop ('Ponte di Legno meeting') report: Vienna, Austria, April 27-28, 2005

Leukemia

Volumn 20, Issue 1, 2006, Pages 9-17

  Gadner, Helmut ^a   Masera, G ^b   Schrappe, M ^c   Eden, T ^d   Benoit, Y ^e   Harrison, C ^f   Nachman, J ^g   Pui, C H ^h  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

AML1 amplification; Asparaginase; Childhood ALL; Down syndrome ALL; Genetic subgroups in T ALL; Induction failure; Minimal residual disease; Secondary cancer; Translocation 1(1; 19)

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CYTARABINE; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; GYRASE INHIBITOR; HYBRID PROTEIN; MEDAC; MERCAPTOPURINE; METHOTREXATE; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC REACTION; ANAPHYLAXIS; AUSTRIA; CANCER GENETICS; CANCER RESEARCH; CANCER THERAPY; CHILDHOOD LEUKEMIA; CHROMOSOME Q BAND; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 19; CLINICAL TRIAL; CONFERENCE PAPER; DIPLOIDY; DOWN SYNDROME; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; GENE AMPLIFICATION; HEALTH CARE ACCESS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFECTION COMPLICATION; MEDICAL ETHICS; OCCLUSIVE CEREBROVASCULAR DISEASE; PANCREATITIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SECOND CANCER; THROMBOEMBOLISM; THROMBOSIS; TREATMENT FAILURE; TREATMENT PLANNING; WORKSHOP;

EID: 33644990008     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404016     Document Type: Conference Paper

References (56)

1. Pui CH, Evans WE, Gilbert JR. Meeting report: International childhood ALL workshop: Memphis, TN, 3-4 December 1997. Leukemia 1998; 12: 1313-1318.
2. Pui CH, Schrappe M, Camitta B. Normal and malignant hemopoiesis: spotlight on long-term results of pediatric ALL clinical trials from study 12 groups world wide. Leukemia 2000; 14: 2193-2320.
3. Pui CH, Ribeiro RC. International collaboration on childhood leukemia. Int J Hematol 2003; 78: 383-389.
4. Aricó M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
5. Pui CH, Sallan S, Relling MV, Masera G, Evans WE. International childhood acute lymphoblastic leukemia workshop: Sausalito, CA, 30 November-1 December 2000. Leukemia 2001; 15: 707-715.
6. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-1915.
7. Pui CH, Chessell JM, Camitta B, Baruchel A, Biondi A, Boyett JM et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003; 17: 700-706.
8. Gadner H, Haas OH, Masera G, Pui C-H, Schrappe M. 'Ponte di Legno' working group - report on the fifth international childhood acute lymphoblastic leukemia workshop: Vienna, Austria, 29 April - 1 May 2002. Leukemia 2003; 17: 798-803.
9. Heerema NA, Harbott J, Galimberti S, Valsecchi MG, Camitta BM, Gaynon PS et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are non-random and may be associated with outcome. Leukemia 2004; 18: 693-702.
10. Pui CH, Schrappe M, Masera G, Nachman J, Gadner H, Eden OB et al. Ponte di Legno Working Group: Statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. Leukemia 2004; 18: 1043-1053.
11. Aricó M, Baruchel A, Bertrand Y, Biondi A, Conter V, Eden T et al. The seventh international childhood acute lymphoblastic leukemia worskshop report: Palermo, Italy, January 29-30, 2005. Leukemia 2005; 19: 1145-1152.
12. Vieira Pinheiro JP, Boos J. The best way to use asparaginase in childhood acute lymphoblastic leukaemia - still to be defined? Br J Haematol 2004; 125: 117-127.
13. Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 1527-1533.
14. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 1525-1532.
15. Hak LJ, Relling MV, Cheng C, Pei D, Wang B, Sandlund JT et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004; 18: 1072-1077.
16. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2002; 99: 1986-1994.
17. Vieira Pinheiro JP, Lanvers C, Würthwein G, Beier R, Casimiro Da Palma J, Von Stackelberg A et al. Drug monitoring of PEG-asparaingase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43: 1911-1920.
18. Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004; 10: 5335-5341.
19. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): Long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-2239.
20. Ng A, Taylor GM, Eden OB. Treatment related Leukaemia - a clinical and scientific challenge. Cancer Treat Rev 2000; 26: 377-391.
21. Thomsen JB, Schroder H, Kristinsson J, Madsen B, Szumlanski C, Weinshilboum R et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: Relation to thiopurine metabolism. Cancer 1999; 86: 1080-1086.
22. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354: 34-39.
23. Masera G, Eden T, Schrappe M, Nachman J, Gadner H, Gaynon P et al. Position Statement: Statement by members of the Ponte di Legno Group on the Rights of children to have full access to essential treatment for acute lymphoblastic leukaemia. Pediatr Blood Cancer 2004; 43: 103-104.
24. Eden T, Pui CH, Schrappe M, Tognoni G, Masera G. All children have the right to full access to treatment for cancer. Lancet 2004; 364: 1121-1122.
25. Global Action Against Cancer. World Health Organisation and UICC, 2003 ISBN 92 4 1590726.
26. Barr RD, Sala A, Masera G, Mato G, Antillon F, Castillo L et al. A formulary for pediatric oncology in developing countries. Pediatr Blood Cancer 2005; 44: 433-435.
27. Harewood L, Robinson H, Harris R, Al Obaidi MJ, Jalali GR, Martineau M et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: A study of 20 cases. Leukemia 2003; 17: 547-553.
28. Robinson HM, Broadfield ZJ, Cheung KL, Harewood L, Harris RL, Jalali GR et al. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 2003; 17: 2249-2250.
29. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: Clinical features and molecular pathogenesis. Blood 1996; 87: 1211-1224.
30. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. Blood 2000; 95: 3310-3322.
31. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000; 14: 2223-2233.
32. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmudsson G et al. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia 2000; 14: 2267-2275.
33. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000; 14: 2276-2285.
34. Pui C-H, Boyett JM, Rivera GK, Hancock ML, Sandlund JT, Ribeiro RC et al. Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14: 2286-2294.
35. Eden OB, Harrison G, Richards S, Lilleyman JS, Bailey CC, Chessells JM et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Leukemia 2000; 14: 2307-2320.
36. Pui C-H, Sandlund JT, Pei D, Rivera GK, Howard SC, Ribeiro RC et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003; 290: 2001-2007.
37. Kager L, Cheok M, Yang W, Zaza G, Cheng Q, Panetta JC et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005; 115: 110-117.
38. Secker-Walker LM, Berger R, Fenaux P, Lai JL, Nelken B, Garson M et al. Prognostic significance of the balanced t(1;19) and unbalanced der(19)t(1;19) translocations in acute lymphoblastic leukemia. Leukemia 1992; 6: 363-369.
39. Pui C-H, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19)(q23;p13) or its derivative. J Clin Oncol 1994; 12: 2601-2606.
40. Uckun FM, Sensel MG, Sather HN, Gaynon PS, Arthur DC, Lange BJ et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: A report from the Children's Cancer Group. J Clin Oncol 1998; 16: 527-535.
41. Bernard OA, Busson-LeConiat M, Ballerini P, Mauchauffe M, Della Valle V, Monni R et al. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia 2001; 15: 1495-1504.
42. Su XY, Busson M, Della Valle V, Ballerini P, Dastugue N, Talmant P et al. Various types of rearrangements target TLX3 locus in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2004; 41: 243-249.
43. Ballerini P, Blaise A, Busson-Le Coniat M, Su XY, Zucman-Rossi J, Adam M et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 2002; 100: 991-997.
44. van der Burg M, Poulsen TS, Hunger SP, Beverloo HB, Smit EM, Vang-Nielsen K et al. Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia. Leukemia 2004; 18: 895-908.
45. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
46. Berger R, Dastugue N, Busson M, van den AJ, Perot C, Ballerini P et al. A collaborative study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Leukemia 2003; 17: 1851-1857.
47. Cave H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: Results of EORTC studies. Blood 2004; 103: 442-450.
48. Barber KE, Martineau M, Harewood L, Stewart M, Cameron E, Strefford JC et al. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 2004; 18: 1153-1156.
49. Kim HJ, Woo HY, Koo HH, Tak EY, Kim SH. ABL oncogene amplification with p16(INK4a) gene deletion in precursor T-cell acute lymphoblastic leukemia/lymphoma: Report of the first case. Am J Hematol 2004; 76: 360-363.
50. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084-1089.
51. Zeller BG, Gustafsson E, Forestier J, Abrahamsson N, Clausen J, Heldrup L et al. Acute leukaemia in children with Down syndrome: A population-based Nordic study. Br J Haematol 2005; 128: 797-804.
52. Ravindranath Y. Down syndrome and leukemia: New insights into the epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer 2005; 44: 1-7.
53. Izraeli S. Congenital syndromes and leukemia: Clues to pathogenesis. Rev Clin Exp Hematol 2003; 7: 246-260.
54. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5: 11-20.
55. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000; 110: 512-524.
56. Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 2005; 44: 21-28.